PCM
BDTX icon

Prelude Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Prelude Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6K Buy
+13,895
New +$33K ﹤0.01% 1151
2022
Q4 		– Sell
-10,541
Closed -$18K – 1334
2022
Q3 		$18K Buy
+10,541
New +$32.5K ﹤0.01% 1279
2022
Q1 		– Sell
-11,483
Closed -$61K – 1830
2021
Q4 		$61K Buy
+11,483
New +$80.2K ﹤0.01% 1767

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Prelude Capital Management's BDTX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Black Diamond Therapeutics (BDTX) in Q1 2026: 13,895 shares worth $29.6K. The stake represents ﹤0.01% of the portfolio and ranks #1151 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in BDTX as recently as Q3 2022.

Prelude Capital Management first reported a position in BDTX in Q4 2021 and has held it in 3 quarters since. The position peaked at $61K in Q4 2021. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Prelude Capital Management held 13,895 shares of Black Diamond Therapeutics worth $29.6K as of Q1 2026.
  • Black Diamond Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1151 holding.
  • Prelude Capital Management first reported a position in Black Diamond Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • Prelude Capital Management's Black Diamond Therapeutics position peaked at $61K in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.